Research Analysts Offer Predictions for DVAX Q1 Earnings

Dynavax Technologies Co. (NASDAQ:DVAX) – Research analysts at William Blair decreased their Q1 2025 earnings per share estimates for Dynavax Technologies in a research report issued on Friday, February 21st. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will earn $0.03 per share for the quarter, down from their prior estimate of $0.04. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.32 per share. William Blair also issued estimates for Dynavax Technologies’ Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.28 EPS, Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.11 EPS and FY2026 earnings at $0.61 EPS.

Several other equities analysts have also commented on DVAX. StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday. The Goldman Sachs Group lowered Dynavax Technologies from a “neutral” rating to a “sell” rating and dropped their target price for the company from $15.00 to $12.00 in a report on Tuesday, February 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st.

Dynavax Technologies Stock Down 0.1 %

Dynavax Technologies stock opened at $13.41 on Monday. The firm has a market capitalization of $1.76 billion, a P/E ratio of 74.50 and a beta of 1.32. The stock’s fifty day simple moving average is $12.83 and its 200-day simple moving average is $12.06. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies has a twelve month low of $9.74 and a twelve month high of $14.05.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The business had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million.

Hedge Funds Weigh In On Dynavax Technologies

Several hedge funds have recently made changes to their positions in DVAX. Creative Planning grew its holdings in shares of Dynavax Technologies by 77.2% during the third quarter. Creative Planning now owns 26,817 shares of the biopharmaceutical company’s stock worth $299,000 after purchasing an additional 11,682 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Dynavax Technologies during the third quarter worth about $8,291,000. Nisa Investment Advisors LLC grew its holdings in shares of Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,679 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Dynavax Technologies by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 25,204 shares of the biopharmaceutical company’s stock worth $281,000 after purchasing an additional 9,827 shares during the last quarter. Finally, US Bancorp DE grew its holdings in shares of Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,034 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.